activity of GS. K , for glutamate is 1.8 mM (Cooper et al., 1983) . The inhibitor L-methionine-S-sulphoximine (MSO) binds to both the glutamate-and ammonia-binding sites. MSO is a strong irreversible inhibitor of GS, and administration of MSO to animals produces generalized convulsions (Cooper et al., 1983) .
GS is mainly, if not exclusively, localized in the cytoplasm of astrocytes (Norenberg & Martinez-Hernandez, 1979) . This discovery led to the suggestion that the astrocytes comprised a compartment in the brain engaged in the the synthesis of glutamine. High concentrations of GS are also demonstrated in primary astrocyte cultures (Schousboe et al., 1977) . Juurlink et al. (1981) have demonstrated GS actively in these cultures by immunohistochemical studies. The immunohistochemical presence of GS in cultured astrocytes and its absence in oligodendrocytes have been reported by Raff et al. ( 1 983) .
The sheep brain enzyme has an apparent molecular mass of 392kDa and is composed of eight identical studies arranged as a cube (Levintow & Meister, 1955) . GS actively has been detected in every structure examined in human brain (Vogel et al., 1975) and in adult cat brain (Berl, 1966) .
The maximum specific activity obtained in cultured glial cells is twice that of brain as a whole (Schousboe et al., 1977) . Developmental studies of GS have shown that the specific activity of GS increases sharply in vivo during the first 2 weeks after birth. This holds true both for cerebellum and cerebal cortex (Drejer et al., 1985; Larsson et al., 1985) (for review, see Cooper et al., 1983; Meister, 1985) . Phosphate-activated glutaminase (PAG) catalyses the hydrolytic cleavage of glutamine, yielding glutamate and ammonia. The reaction is for practical purposes irreversible. The enzymic activity has a broad pH dependence curve, as Abbreviations used: GS, glutamine synthetase; MSO, L-methionine-S-sulphoximine; PAC, phosphate-activated glutaminase, GABA, y-aminobutyrate.
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shown by several investigators (for review, see Kvamme, 1984) . PAC is shown to be an allosteric enzyme (Svenneby, 1971) . A lot of di-and tri-carboxylic acids, in addition to phosphate and sulphate, activate the enzyme (O'Donovan & Lotspeich, 1966; Weil-Malherbe, 1969; Svenneby, 1971) , as do calcium (Kvamme et al., 1983) and acyl-CoA derivatives (Kvamme & Torgner, 1984) (for review, see Kvamme, 1984; Kvamme et al., 1985) . Glutamate, one of the reaction products, inhibits PAC, whereas both inhibition and activation by ammonia have been described. No significant difference concerning the kinetic properties is detected between the enzyme from either mammalian kidney or brain.
PAG is localized in the mitochondria, presumably in the inner mitochondria1 membrane (for review see Kvamme, 1984) . The brain enzyme from all mammals so far investigated, in addition to that of fish and bird, is built up of identical subunits with a molecular mass of approx. 64 kDa (Svenneby et a[., 1973,19866) , except rat brain PAG, which consists of two different subunits with molecular masses of approx. 64 and 67 kDa (Svenneby et al., 19866) , respectively. Immunological studies have shown that the 67 kDa subunits account for about one-quarter of the total enzyme . The presence of apparent identical immunoreactivity in the above mentioned species reveals a rather conservative enzyme, which explains our problems in raising PAG-antibodies with higher titre. The dissociated subunit of PAG is enzymically inactive. The subunit can be dimerized to an active species, or aggregated to higher aggregates with molecular mass to up to about 2000 kDa (Svenneby, 1971) . The higher aggregates increase in specific activity. The dimeric enzyme seems to have low or no activity in the absence of activator (e.g. phosphate), whereas the more aggregated forms are active in the absence of activator. Phosphate promotes dimerization of the enzyme, aggregation of the dimer enzyme form to tetrameric form, whereas borate in addition to phosphate enhances the aggregation to higher molecular mass species (Svenneby et al., 1973) .
There seem to be some discrepancies between investigations concerning inhibition. Competetive, non-competitive and mixed competitive glutamate inhibition have all been described (Svenneby, 1971; Chiu & Boecker, 1979; Nimmo & Tipton, 1981; Shapiro et al., 1982) .
Recently we have obtained evidence for two kinetically different PAG species in the mitochondria. One form is soluble or weakly associated with the membrane, and has a high K , ( 2 0 -4 0 m~) . The other form is tightly associated with the membrane, and the K, is much lower (about 2 mM). Both forms are competitively inhibited by both glutamate and ammonia. However, when kinetic studies are performed BIOCHEMICAL SOCIETY TRANSACTIONS in a mixture of both forms, the inhibition pattern of glutamate will apparently be non-competitive unless measurements at high substrate concentrations are performed (Torgner et al., 1986) . This may be a reason for the diverging glutamate kinetics reported by different investigators. In the presence of ammonia, the enzyme displays co-operative substrate binding. The inhibitory effect of ammonia is therefore only recognized at a low substrate concentrations. This may explain why ammonia was found to be without inhibitory effect in some investigations (Svenneby, 1971; Nimmo & Tipton, 1981; Kvamme et al., 1983) . The inhibition by ammonia never exceeds 50%, thus the inhibition can not be purely competitive, since in competitive inhibition increasing the inhibitor concentration sufficiently should result in complete inhibition.
PAG seems to be present in neurons as well as glial cells, as shown by both measuring the enzymic activity (Drejer et al., 1985; Larsson et al., 1985) and identifying PAG-like immunoreactivity in cultures of cerebral granule cells, of cerebral cortex interneurons and of astrocytes (Svenneby et al., 19866) .
PAG is detected in all the brain areas and, in contrast to GS, PAG is present in glial cells as well as in neurons (Drejer et a[., 1985; Larsson et al., 1985; Svenneby et al., 19866) . McGeer & McGeer (1979) have postulated that 60% of PAG in neostriatum is localized in GABAergic structures. By immunohistochemical methods using antibodies against pig brain PAG (Svenneby & Storm-Mathisen, 1983) , we have shown that the distribution of PAG-like immunoreactivity indicates the presence of PAG in all cell types. However, others using antibodies raised against rat kidney PAG observed an enrichment of PAG-like immunoreactivity in neurons expected to use exitatory amino acids as transmitters Donoghue et al., 1985) . According to Butterworth et al. (1985) PAG is not evenly distributed throughout the human brain.
Developmental studies of PAG (Drejer et al., 1985; Larsson et al., 1985) revealed no significant difference between cultured cortical neurons and brain cortex, or between glutamatergic or GABAergic neurons in culture (cerebellar granule cells and cerebral cortex interneurons, respectively). When PAG was determined in the presence of low concentrations of phosphate, the specific activity in all cases increased only slightly as a function of age. The activity of PAG in astrocytes is similar to that in neonatal and adult whole brain (Juurlink et al., 1981) . As far as PAG has been investigated in human brain autopsies, we have not observed any significant difference from the results found for PAG from other sources (Svenneby et al., 1986~) .
In conclusion, GS catalyses the synthesis of glutamine in glial cells, a part of which is the precursor for transmitter glutamate. However, with respect to PAG, much more knowledge must be obtained before anything conclusive can be said about its role in the process of producing transmitter glutamate, and also GAB,4.
What about the function of GS and PAG? There is no close connection between these two enzymes. GS is localized, as mentioned previously, in the cytosol of astrocytes, whereas PAG apparently exists in the same amount in astrocytes and neurons. Furthermore, PAG is localized mostly attached to the inner mitochondria1 membrane. GS is involved in an energy-dependent process (requiring ATP), whereas PAG does not catalyse the reverse reaction of GS, but the hydrolytic cleavage of glutamine. GS is apparently the only enzyme involved in the synthesis of glutamine (Meister, 1974) and has a significant role in detoxification. Furthermore, glutamine participates in several amide-and amine-transfer reactions in which ammonia could have played the same role. Interesting also is the dual effect of phosphate on PAG and GS, activation and inhibition, respectively. Glutamate, one of the substrates for the GS reaction and also one of the products of the PAG reaction, is used both for neurotransmission as well as for metabolic purposes. The importance of PAG in producing transmitter glutamate is difficult to verify. It is well documented that there are two glutamate-glutamine pools in the brain (Berl et al., 1962; Berl, 1973) . Cerebral glutamine is synthesized in a small, metabolically active glutamate pool that has a slower turnover. Astrocytes are believed to be the small compartment (Van den Berg & Garfinkel, 1971; Berl, 1973) , whereas the 'big pool' of glutamate is considered to be in the neurons (Berl, 1973) . Furthermore, glutamine is likely to be a precursor for the releasable pool of glutamate as well as of GABA (Hamberger ef al., 1979~) . Evidence has been obtained that the newly synthesized glutamate from glutamine is released from the nerve terminals by excitation (Hamberger et al., 1979b) .
Moreover, glutamine influx is increased under conditions of stimulated glutamate release (Hamberger et al., 19796) . In this connection, our observation of two glutaminase forms with low and high K,,, values for glutamine, might have relevance. The enzyme form with the high K , will be much more active under increased influx of glutamine, and might thereby be the enzyme form responsible for transmitter glutamate production. Neurochemists are preferentially interested in some compounds present in brain not only in order to progress our knowledge of brain function but also in view of their usefulness for man. Is y-hydroxybutyrate (GHB) such a compound? The answer seems to be yes.
GHB is a four-carbon compound with potent neurophysiological and neuropharmacological properties. Considering the analogy with y-aminobutyrate (GABA), it was synthesized in 1960 (Jouany et al., 1960; Laborit et al., 1960) in an attempt to provide a GABA-mimetic drug which crosses the blood brain-barrier. Later on, GHB was found to be a natural compound in the central nervous system (Bessman & Fishbein, 1963; Roth, 1970) . GHB and its congener, y-butyrolactone (GBL), administrated systemically both produce similar pharmacological, behavioural and electroencephalographic effects, namely those of a type of seizures 'petit mal' (Snead, 1984 ). An active lactonase has been found in liver and in serum, but not in brain or spinal fluid, that converts GBL to GHB. (Roth et al., 1967) . Applied iontophoretically, GHB depresses the firing of cortical and nigrostriatal neurons in rats (Olpe & Koella, 1979) . This effect is not blocked by bicuculline, suggesting that GHB does not interact with GABA receptors. Like GABA, but not mediated by GABA receptors, GHB increases the level of dopamine in the substantia nigra and decreases the impulse flow in the dopaminergic neurons (Roth et al., 1973) . GHB, injected intraperitoneally at a rather high dosage, produces a dose-dependent increase of 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid in the corpus striatum and to a lesser extent in the mesolimbic area and the cortex (Waldmeier & Fehr, 1978; Hedner & Lundborg, 1983) . The site of interaction of GHB with the 5-hydroxytryptaminergic system remains an open question. A rather high dosage of GHB or GBL produces in the rat an increase of acetylcholine in specific brain areas: midbrain, hippocampus and cortex (Giarman & Schmidt, 1963; Ladinsky et al., 1983) .
About 7 years ago, we suggested that GHB is a satisfactory candidate for neurotransmitter function. In this paper we will mainly consider the evidence in favour of this assumption. The criteria generally accepted for a compound to be recognized as a neurotransmitter are the following:
(1) evidence that application of the substance reproduces Abbreviations used: GHB, y-hydroxybutyrate; GABA, y-aminobutyrate: GBL, y-butyrolactone; 5-HT, 5-hydroxytryptamine; SSA, succinic semialdehyde; SSR, succinic semialdehyde reductase; GABA-T, p-aminobutyrate : 2-oxoglutarate transaminase. a specific event of synaptic transmission (excitatory or inhibitory), (2) evidence of its release after stimulation, (3) evidence of necessary precursors and enzyme(s) which synthesize the transmitter in presynaptic nerve terminals, (4) presence of a mechanism(s) which inactivates the transmitter, (5) evidence that the concentration of the transmitter varies with functional activity, (6) evidence of action of agonists and of antagonists related to the transmitter, (7) identification of the neuronal organization.
In the remainder of this paper we will try to demonstrate that GHB fullfils these criteria.
Biosynthesis of y-hydroxybutyrate
When GABA is transaminated in presence of cr-ketoglutarate the products of the reaction are glutamate and succinic semialdehyde (SSA) (Baxter, 1970) . Although this reaction is reversible in vitro, there is no evidence that it occurs in vivo (Baxter & Roberts, 1961) . This is due most probably to the presence in the same mitochondria1 compartment of a highly active NAD-linked dehydrogenase, succinic semialdehyde dehydrogenase, which oxidises SSA to succinate.
The concentration of SSA detected in brain of about IO-'M is strikingly lower than its K,,, for the reverse transamination reaction (see Cash et al., 1979~). However, brain tissue is also capable of reducing SSA to GHB; the enzymes responsible have been identified and characterized in rat and human brain as NADPH-linked aldehyde reductases. (Fishbein & Bessman, 1964; Roth & Giarman, 1970; Ris & Von Wartburg, 1973; Matsuda & Hoshino, 1977; Rumigny et a[., 1980; Ryle & Tipton, 1981; Turner & Tipton, 1972) . These enzymic activities have a regional distribution similar to that of GHB.
We purified to electrophoretic homogeneity two major aldehyde reductases capable of reducing SSA to GHB from both human and rat brains (Rumigny et al., 1980; Cash et al., 1979b) . In both cases there are two major enzymes which can catalyse this reaction. These two enzymes were separated by DEAE-cellulose chromatography and then extensively purified to electrophoretic homogeneity. The substrate specificities of the enzymes isolated from human and rat brains were compared. It appeared that one enzyme, SSR,, is fairly specific, acting quite exclusively on the substrate SSA, whereas the other, SSR,, is most active with classical aldehyde reductase substrate, p-nitrobenzaldehyde and others. Unlike the non-specific SSA reductase which is a monomer of M, about 48000, the specific enzyme is a dimer with an M,.of about 82000. The SSR, enzyme is strongly inhibited by barbiturates, which are inhibitors of many prev;ously described aldehyde reductases, and by the anticonvulsant drug valproic acid and other branched-chain fatty acids (Turner & Tipton, 1972; Cash et al., 1979a Whittle & Turner, 1978 Javors & Erwin, 1980; Rumigny et al., 1980) . Barbiturates and the branched-chain fatty
